In this issue
Neoadjuvant chemotherapy
Scaling up cancer diagnosis and treatment in developing countries
Status of PI3K inhibition and biomarker development in cancer therapeutics
EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts’ opinion for the treatment of non-small-cell lung cancer in an elderly population
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients
The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
Analysis of local and regional recurrences in breast cancer after conservative surgery
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
Absence of transforming growth factor-β type II receptor is associated with poorer prognosis in HER2-negative breast tumours
Genetic testing in young women with breast cancer
Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older
Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs)
Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer
A phase II study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer
Outcome following resection for patients with primary mediastinal nonseminomatous germ-cell tumors and rising serum tumor markers post-chemotherapy
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology
High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors
JC human polyomavirus is associated to chromosomal instability in peripheral blood lymphocytes of Hodgkin’s lymphoma patients and poor clinical outcome
Prognostic significance of S-phase kinase-associated protein 2 and p27kip1 in patients with diffuse large B-cell lymphoma
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL)
Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions
Gemcitabine as single agent in pretreated T-cell lymphoma patients
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy
Psychological distress among male patients and male spouses
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours
Global drug development in cancer
Discordant expression of molecular markers between primary and nodal metastases
Sudden death during adjuvant trastuzumab therapy of breast cancer
Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy
Reply to Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated with radiotherapy combined or not with androgen deprivation therapy
Erythropoiesis-stimulating agents (ESAs), from chemotherapy-induced anemia to any cancer-related anemia?
Eccrine porocarcinoma presenting with scrotal lymphedema
Spirituality and religion in cancer
Darwin's gemmules and oncogenes